284,792 results on '"SECURITIES LAW"'
Search Results
2. Must a Company Disclose to Investors That a Risk Has Already Occurred, Even if There Is No Known Risk of Future Business Harm?
3. SEC rule confusion continues to put CISOs in a bind a year after a major revision
4. What CISOs need to know about the SEC’s breach disclosure rules
5. Do minority shareholder protection laws benefit investors? Evidence from a natural experiment on cross-listed firms
6. Xortx Therapeutics Inc. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Jan. 6, 2025)
7. Sunshine Biopharma Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933: (Jan. 6, 2025)
8. Protagenic Therapeutics, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Jan. 6, 2025)
9. Nok Therapeutics, Inc. Files SEC Form QUALIF, Notice of Qualification [Regulation A]: (Jan. 3, 2025)
10. Neurosense Therapeutics Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Jan. 6, 2025)
11. Cytomed Therapeutics Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Jan. 6, 2025)
12. Briacell Therapeutics Corp. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Jan. 3, 2025)
13. Alterity Therapeutics Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Jan. 6, 2025)
14. Aeon Biopharma, Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Jan. 6, 2025)
15. Zyversa Therapeutics, Inc. Files SEC Form 424B3, Prospectus [Rule 424(B)(3)]: (Dec. 30, 2024)
16. Xtl Biopharmaceuticals Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 30, 2024)
17. Vivos Therapeutics, Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 26, 2024)
18. Protagenic Therapeutics, Inc. Files SEC Form 424B3, Prospectus [Rule 424(B)(3)]: (Dec. 27, 2024)
19. Palvella Therapeutics, Inc. Files SEC Form S-1, General Form For Registration of Securities Under The Securities Act of 1933: (Dec. 31, 2024)
20. Northwest Biotherapeutics Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 26, 2024)
21. Kazia Therapeutics Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 31, 2024)
22. Kazia Therapeutics Ltd Files SEC Form 424B3, Prospectus [Rule 424(B)(3)]: (Dec. 31, 2024)
23. Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 30, 2024)
24. Alterity Therapeutics Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 31, 2024)
25. Aclaris Therapeutics, Inc. Files SEC Form 424B3, Prospectus [Rule 424(B)(3)]: (Dec. 31, 2024)
26. Zyversa Therapeutics, Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933: (Dec. 20, 2024)
27. Xortx Therapeutics Inc. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 19, 2024)
28. Quantum Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 20, 2024)
29. Protagenic Therapeutics, Inc. Files SEC Form S-1, General Form For Registration of Securities Under The Securities Act of 1933: (Dec. 20, 2024)
30. Phio Pharmaceuticals Corp. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 23, 2024)
31. Nok Therapeutics, Inc. Files SEC Form 1-A/A, Offering Statement [Regulation A]: (Dec. 23, 2024)
32. Neurosense Therapeutics Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 23, 2024)
33. Monopar Therapeutics Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 23, 2024)
34. Lakeshore Biopharma Co., Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 19, 2024)
35. Indaptus Therapeutics, Inc. Files SEC Form S-1, General Form For Registration of Securities Under The Securities Act of 1933: (Dec. 23, 2024)
36. Gt Biopharma, Inc. Files SEC Form S-1, General Form For Registration of Securities Under The Securities Act of 1933: (Dec. 23, 2024)
37. Cosciens Biopharma Inc. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 23, 2024)
38. Connect Biopharma Holdings Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 23, 2024)
39. Cadrenal Therapeutics, Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 20, 2024)
40. Aptevo Therapeutics Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933: (Dec. 20, 2024)
41. Altamira Therapeutics Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 20, 2024)
42. Aclaris Therapeutics, Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933: (Dec. 19, 2024)
43. Pou Chen announces monthly sales for December 2024
44. Xortx Therapeutics Inc. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 12, 2024)
45. Xortx Therapeutics Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 13, 2024)
46. Trevi Therapeutics, Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)]: (Dec. 16, 2024)
47. Taysha Gene Therapies, Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933: (Dec. 13, 2024)
48. Relief Therapeutics Holding Sa Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 16, 2024)
49. Relief Therapeutics Holding Sa Files SEC Form 424B3, Prospectus [Rule 424(B)(3)]: (Dec. 17, 2024)
50. Nok Therapeutics, Inc. Files SEC Form 1-A/A, Offering Statement [Regulation A]: (Dec. 17, 2024)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.